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Pyruvate dehydrogenase complexds as well as their CoA and carnitine esters in tissues and body ﬂuids is a common
ﬁnding in organic acidurias, beta-oxidation defects, Reye syndrome, and Jamaican vomiting sickness.
Pathomechanistic approaches for these disorders have been often focused on the effect of accumulating
organic acids on mitochondrial energy metabolism, whereas little is known about the pathophysiologic role
of short- and medium-chain acyl-CoAs and acylcarnitines. Therefore, we investigated the impact of short-
and medium-chain organic acids, acylcarnitines, and acyl-CoAs on central components of mitochondrial
energy metabolism, namely alpha-ketoglutarate dehydrogenase complex, pyruvate dehydrogenase complex,
and single enzyme complexes I-V of respiratory chain. Although at varying degree, all acyl-CoAs had an
inhibitory effect on pyruvate dehydrogenase complex and alpha-ketoglutarate dehydrogenase complex
activity. Effect sizes were critically dependent on chain length and number of functional groups.
Unexpectedly, octanoyl-CoA was shown to inhibit complex III. The inhibition was noncompetitive regarding
reduced ubiquinone and uncompetitive regarding cytochrome c. In addition, octanoyl-CoA caused a blue
shift in the gamma band of the absorption spectrum of reduced complex III. This effect may play a role in the
pathogenesis of medium-chain and multiple acyl-CoA dehydrogenase deﬁciency, Reye syndrome, and
Jamaican vomiting sickness which are inherited and acquired conditions of intracellular accumulation of
octanoyl-CoA.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionShort- and medium-chain organic acids and acyl-CoAs are
generated by the mitochondrial breakdown of fatty acids and
some amino acids. Degradation of these metabolites generates
energy substrates for tricarboxylic acid (TCA) cycle and respiratory
chain. Beside catabolism they play an important role during
anabolism by providing C-atom backbones for biosynthesis of a
vast number of cellular components. Whereas amino acids or the
corresponding alpha-keto acids cross the mitochondrial membrane
via speciﬁc carrier systems and are further degraded, mitochondrial
import of fatty acids involves a complex transport system. Long-
chain fatty acidsare activated by acyl-CoA synthase and areketoglutarate dehydrogenase
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ll rights reserved.converted in an acylcarnitine by carnitine palmitoyltranferase I,
both steps taking place at the outer mitochondrial membrane [1].
The acylcarnitines are transported from mitochondrial inter-
membrane space into matrix by acylcarnitine translocase and,
subsequently, are converted in an acyl-CoA by carnitine palmi-
toyltransferase II. This carnitine cycle may also function in a reverse
mode when organic acids and acyl-CoAs accumulate in mitochondria
[2] resulting in increased cellular excretion of acylcarnitines.
Accumulation of short- and medium-chain organic acids, acylcarni-
tines, and acyl-CoAs (SMOAA) is a biochemical hallmark of organic
acidurias such as glutaryl-CoA dehydrogenase (GCDH) deﬁciency or
methylmalonic aciduria (MMA), beta-oxidation defects such as
medium-chain acyl-CoA dehydrogenase deﬁciency or short-chain
acyl-CoA dehydrogenase deﬁciency, Jamaican vomiting sickness
(hypoglycin A toxicity due to poisoning with unripe ackee fruit),
and Reye syndrome. It has been speculated that accumulating
SMOAAs play a central role in the pathophysiology of these
metabolic disorders by interfering with mitochondrial energy me-
tabolism. This concept has been studied in detail for GCDH de-
ﬁciency [3–5], propionic aciduria [6] and MMA [7–9]. However, a
systematic approach investigating the impact of SMOAAs on
mitochondrial energy metabolism considering chain length speciﬁ-
city is yet lacking. In contrast, several studies have investigated the
impact of long-chain acyl-CoAs that accumulate in very long-chain
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CoA dehydrogenase deﬁciency on mitochondrial enzymes and
transporters. Long-chain acyl-CoAs revealed to be inhibitors of
citrate synthase, glutamate dehydrogenase, and malate dehydrogen-
ase (palmitoyl-CoA [[10,11]]), succinate-driven oxidative phosphor-
ylation (palmitoyl-CoA [12]), mitochondrial dicarboxylate carrier
(2,3-unsatured, 3-hydroxy-, 3-oxo-, palmitoyl-CoA [13]), ATP/ADP
carrier (long-chain acyl-CoAs [13,14]), PDHc (palmitoyl-CoA [15]),
rotenone-insensitive NADH-cytochrome c oxidoreductase (arachido-
nyl-CoA [16]), and NADH-cytochrome c oxidoreductase (oleoyl-CoA
[17]). However, it has been hypothesized that prominent pathophy-
siologic features of disorders in the degradation of long-chain fatty
acids are mainly caused by the primary lack of energy production,
whereas in disorders of short- and medium-chain fatty acid
degradation accumulating toxic metabolites are likely to induce
secondary pathological changes [18]. To further systematically
evaluate the pathophysiologic role of SMOAAs, we investigated
their impact on central components of mitochondrial energy pro-
duction, namely alpha-ketoglutarate dehydrogenase complex and
pyruvate dehydrogenase complex – the rate limiting enzymes of
TC cycle – as well as single enzyme complexes I–V of respiratory
chain.2. Material and methods
2.1. Reagents
All reagents were purchased from Sigma Aldrich (Taufkirchen,
Germany). We studied the following SMOAAs:
Acylcarnitine: D,L,-acetyl-, propionyl-, butyryl-, isovaleryl-, valeryl-,
hexanoyl-, and octanoylcarnitine.
Organic acids: Acetic, propionic, butyric, isovaleric, valeric,
hexanoic, malonic, methylmalonic, glutaric, and 3-hydroxyglutaric
acid.
Acyl-CoAs: Acetyl (A-CoA)-, propionyl (P-CoA)-, butyryl (B-CoA)-,
isovaleryl (I-CoA)-, hexanoyl (H-CoA)-, octanoyl (O-CoA)-, malonyl
(M-CoA)-, methylmalonyl (MM-CoA)-, and glutaryl (G-CoA)-CoA.
2.2. Preparation of submitochondrial particles from bovine heart
Submitochondrial particles (SMPs) from bovine heart were
prepared as previously described [19]. Protein content was deter-
mined according to Lowry et al. [20] with modiﬁcations [21] using
bovine serum albumin as standard.
2.3. Spectrophotometric analysis of single enzyme complexes I–V of
respiratory chain
Steady state activities of enzyme complexes were recorded using a
computer tunable spectrophotometer (Spectramax Plus Microplate
Reader, Molecular Devices, Sunnyvale, California, U.S.A.) operating in
the dual wavelength mode. Samples were analyzed in temperature-
controlled 96-well plates at a ﬁnal volume of 300 μL. Catalytic
activities of respiratory chain complexes I–V in SMPs were investi-
gated as previously described. In brief, complex I activity was detected
as NADH oxidation [19], complex II activity as dichloroindophenol
reduction [22], complex III activity as cytochrome c reduction [23],
complex IV as cytochrome c oxidation [24], and complex V activity as
NADH reduction in the presence of phosphoenolpyruvate kinase and
lactate dehydrogenase [25]. Addition of standard respiratory chain
inhibitors (complex I: 2-n-decylquinazolin-4-yl-amine [1 μmol/L];
complex II: thenoyltriﬂuoroacetone [8 mmol/L]; complex III: anti-
mycin A [1 μmol/L]; complex IV: NaCN [2 mmol/L]; complex V:
oligomycin [80 μmol/L]) revealed good inhibitory responses (93–100%of control activity, p b0.001 versus controls), conﬁrming speciﬁc
enzyme activity in our assay system. Complex III activity was also
measured using puriﬁed bovine complex III, which was a kind gift of
Prof. Ulrich Brandt (Gustav-Embden-Zentrum der Biologischen Che-
mie, Johann Wolfgang Goethe University, Frankfurt, Germany).
2.4. Spectral shift experiments
Spectral shift experiments were performed using puriﬁed complex
III. Absorption spectra were recorded in a computer tunable spectro-
photometer (Spectramax Plus Microplate Reader, Molecular Devices,
Sunnyvale, California, USA) using microplates. Spectra of oxidized and
reduced enzyme as well as reduced enzyme with a saturating amount
of octanoyl-CoA were recorded. Complex III was reduced by adding
20 nmol sodium dithionite. When reduced spectrum was recorded in
the presence of octanoyl-CoA, the enzymewas incubated ﬁrst with the
inhibitor in a buffer containing 250 mmol/L sucrose, 50 mmol/L KCl,
5 mmol/L MgCl2, and 20mmol/L Tris–HCl (total volume 100 μL, pH 7.4,
25 °C) and was subsequently reduced. Difference spectra were
calculated by Softmax Pro Software deﬁning oxidized or reduced
spectrum as baseline.
2.5 Alpha-ketoglutarate dehydrogenase complex (KGDHc)
KGDHc activity was measured according to Humphries and
Szweda [26] with modiﬁcations. KGDHc (650 mU/mL; puriﬁed from
porcine heart, Sigma-Aldrich) was assayed in a buffer containing
35 mmol/L potassium phosphate, 5 mmol/L MgCl2, 0.5 mmol/L EDTA,
0.5 mmol/L NAD, 0.2 mmol/L thiamine pyrophosphate, 0.04 mmol/L
CoA-SH, and 2 mmol/L alpha-ketoglutarate which was adjusted to pH
7.4 (30°C). KGDHc activity was determined as NAD reduction at
λ=340–400 nm.
2.6. Pyruvate dehydrogenase complex (PDHc)
PDHc activity was investigated according to a recently described
method [27]. In brief, PDHc (160 mU/mL; puriﬁed from porcine heart,
Sigma-Aldrich) was assayed in a buffer containing 0.05 mol/L
potassium phosphate, 2.5 mmol/L NAD, 0.2 mmol/L thiamine
pyrophosphate, 0.1 mmol/L CoA, 0.1% Triton X-100, 1 mmol/L MgCl2,
1 mg/mL bovine serum albumin, 0.6 mmol/L p-iodonitrotetrazolium
violet, and 6.5 μmol/L phenazine methosulfate which was adjusted to
pH 7.4 (25 °C). PDHc activity was determined as p-iodonitrotetrazo-
lium violet reduction at λ=500–750 nm.
2.7. Analyses of inhibition studies
Inhibition studies were analyzed using GraphPad prism 5.01
software for MS Windows. Only doubling or halving of enzyme
activity by SMOAAs at a concentration of 1 mmol/L was considered as
an effect of potential (patho-)physiological relevance.
3. Results
3.1. Octanoyl-CoA inhibits complex III
We investigated the impact of SMOAAs (each 1 mmol/L, in Tris–
HCl pH 7.4) on single enzyme complexes I–V of respiratory chain
using SMPs. The major effect was a strong and concentration-
dependent inhibition of complex III activity by octanoyl-CoA
(1 mmol/L octanoyl-CoA: 78% inhibition). Other acyl-CoAs had no
inhibitory impact or were even activating (e.g. acetyl-CoA: complex
I; butyryl-CoA, malonyl-CoA, complex III; Fig. 1). To exclude that the
inhibition of complex III was an artifact caused by the preparation of
SMPs, we also studied the inhibitory effect of octanoyl-CoA using
puriﬁed complex III revealing similar results as shown for complex
Fig. 1. Impact of short- and medium-chain acyl-CoAs (each 1 mmol/L, in Tris–HCl pH 7.4) on single enzyme complexes I–V of respiratory chain using SMPs. The major effect was a
strong inhibition of complex III activity by octanoyl-CoA (1 mmol/L octanoyl-CoA: 78% inhibition). Other acyl-CoAs had no inhibitory impact or were even activating (e.g. acetyl-CoA:
complex II; butyryl-CoA, malonyl-CoA: complex III). Short dashed lines indicate 50% and 200% of control activity. Activities are given as percent of control. Data are expressed asmean
±S.D., experiments were performed in triplicates.
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charges of octanoyl-CoA from Sigma-Aldrich and Larodan Fine
Chemicals to rule out that the inhibition was caused by contamina-
tions or by-products of CoA-ester synthesis. However, the inhibitory
effect of octanoyl-CoA on complex III was the same in each experi-
mental series.
Neither organic acids nor acylcarnitines affected the activity of any
respiratory chain complex (Table 1) except for the well-known
complex II inhibitor malonate. We also investigated the impact of
octanoic acid on complex III to eliminate the possibility that octanoyl-
CoA was degraded by dissolving and the free organic acid inhibits
complex III. However, octanoic acid did not inﬂuence enzyme activity
(data not shown).Table 1
Impact of short- and medium-chain acylcarnitines and organic acids on single enzyme
complexes I–V of respiratory chain
Complex I Complex II Complex III Complex IV Complex V
M±SD (%) M±SD (%) M±SD (%) M±SD (%) M±SD (%)
l-Acetyl-carnitine 102±1 87±1 105±5 74±5 92±3
Propionyl-carnitine 104±5 95±3 74±5 76±4 92±4
Butyryl-carnitine 107±1 94±4 110±3 89±2 98±2
Isovaleryl-carnitine 84±3 85±3 84±4 97±3 101±3
Valeryl-carnitine 87±3 92±2 83±15 94±4 98±1
Hexanoyl-carnitine 89±3 88±1 94±9 118±19 100±2
Octanoyl-carnitine 93±10 85±2 105±14 96±6 99±1
d-Acetyl-carnitine 98±3 91±1 99±3 110±2 73±4
Acetic acid 92±9 98±5 91±2 99±9 101±3
Propionic acid 114±0 88±5 102±8 105±3 95±4
Butyric acid 111±11 80±8 86±11 93±2 107±95
Isovaleric acid 108±10 80±7 87±1 108±2 111±3
Valeric acid 106±2 84±2 88±3 98±5 99±4
Hexanoic acid 103±13 76±2 95±3 103±1 99±1
Malonic acid 97±6 19±2 102±3 103±5 100±8
Methylmalonic acid 103±15 89±7 96±6 101±2 96±2
Glutaric acid 96±7 99±3 98±4 96±4 94±3
3-Hydroxyglutaric
acid
93±2 103±3 99±11 98±4 94±1
Octanoic acid 110±9
Neither the organic acids nor the acylcarnitines (each 1 mmol/L, in Tris–HCl pH 7.4)
investigated in this study affected the activity of any respiratory chain complex except
for the well-known complex II inhibitor malonate. Activities are given as percent of
control. Data are expressed as mean±S.D. (n=4).3.2. Mode of complex III inhibition by octanoyl-CoA
To further clarify the mode of complex III inhibition by octanoyl-
CoA, we performed inhibition studies with varying concentrations of
octanoyl-CoA (125, 250, 500, 750, and 1000 μmol/L), DBH (1, 5, 12.5,
25, and 50 μmol/L), and cytochrome c (4, 7.5, 15, 30, and 60 μmol/L).
The inhibition was concentration-dependent (octanoyl-CoA, 0.05,
0.125, 0.25, 0.5, 0.5, 1, 2, and 3 mmol/L; Fig. 2A). Nonlinear regression
analysis revealed that octanoyl-CoA-induced inhibition was noncom-
petitive regarding DBH (Vmax: 2.9±0.7 U/mg, Km: 44.8±19 μmol/L, Ki:
728±74.7 μmol/L; difference in AICs: noncompetitive vs. competitive,
−1.6; noncompetitive vs. uncompetitive, −12.5; noncompetitive vs.
mixed model inhibition, −2.6) and uncompetitive regarding cyto-
chrome c (Vmax: 2.9±0.7 U/mg, Km: 26.3±13.49 μmol/L, αKi: 184.0±
27.8 μmol/L; difference in AICs: uncompetitive vs. noncompetitive,
−12.1; uncompetitive vs. competitive, −32.6; mixed model inhibition
ambiguous) (Fig. 2B, C) indicating that octanoyl-CoA does not directly
interact with DBH or cytochrome c binding site.
3.3. Effects of octanoyl-CoA on the absorption spectrum of complex III
When octanoyl-CoA was added to reduce complex III, it had a
hypsochromic effect and caused a blue shift in the gamma band of the
absorption spectrum of reduced complex III. The blue shift resulted in a
difference spectrum with a maximum at 412 nm and a minimum at
431 nm. This effect was concentration-dependent and, thus, higher
concentrations of octanoyl-CoA intensiﬁed the blue shift. The alpha
band did not show a blue shift but a minimum at 561 nm. The cy-
tochrome c peak at 555 nmwas less affected. The effect of octanoyl-CoA
on reduced absorption spectrum of complex III suggests that octanoyl-
CoA inhibits the reduction of cytochrome b (Fig. 3A). Difference spectra
of oxidized and in the presence of an inhibitor reduced enzyme further
underline this suggestion. Increasing amounts of octanoyl-CoA caused a
concentration-dependent decrease of cytochrome b peak in the alpha
band at 560 nm, whereas reduction of cytochrome c peak at 555 nm
was less reduced (Fig. 3B). In summary, spectral data indicate that
octansoyl-CoA reduces complex III activity by inhibiting the reduction of
cytochrome b. To exclude a general effect of medium-chain acyl-CoAs,
we also incubated reduced complex III with hexanoyl-CoA. In contrast
to octanoyl-CoA, this acyl-CoA did not affect the absorption spectrum of
complex III (data not shown).
Fig. 2. Mode of complex III inhibition by octanoyl-CoA. Inhibition studies were performed
with varying concentrationsof octanoyl-CoA (125, 250, 500, 750, and 1000 μmol/L), DBH (1,
5, 12.5, 25, and 50 μmol/L) and cytochrome c (4, 7.5, 15, 30, and 60 μmol/L). Inhibition was
concentration-dependent (a). Nonlinear regression analysis revealed that the inhibition
was noncompetitive regarding DBH (Vmax: 2.9±0.7 U/mg, Km: 44.8±19 μmol/L, Ki: 728±
74.7 μmol/L; (b) and uncompetitive regarding cytochrome c (Vmax: 2.9±0.7 U/mg,Km: 26.3
± 13.49 μmol/L, alpha-Ki: 184.0±27.8 μmol/L; (c). Activities are given as mOD/min. All data
are expressed as mean, experiments were performed in triplicates.
Fig. 3. Effect of octanoyl-CoA on absorption spectrum of complex III. Incubation of
reduced complex III with octanoyl-CoA caused a blue shift in the gamma band of the
absorption spectrum of reduced complex III with a maximum at 412 nm and a
minimum at 431 nm. This effect was concentration-dependent and higher octanoyl-
CoA concentrations intensiﬁed the blue shift. The alpha band did not show a blue shift
but a minimum at 561 nm that is likely to refer to cytochrome b562 (A). Difference
spectra of oxidized and in presence of an inhibitor reduced enzyme displayed that
increasing amounts of octanoyl-CoA cause a concentration-dependent decrease in the
alpha band at 560 nm (cytochrome b562 peak), whereas the cytochrome c peak at
555 nm was less affected (B). These ﬁndings suggest that octanoyl-CoA inhibits the
reduction of cytochrome b562.
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dehydrogenase complex (PDHc)
We investigated the impact of SMOAAs (each 250, 500, and
1000 μmol/L, in Tris–HCl, adjusted to pH 7.4) on PDHc activity. All
investigated acyl-CoAs inhibited PDHc activity but by a varying degree
depending on chain length and number of carboxylic groups (Fig. 4).
Short-chainmonocarboxylic acyl-CoAs revealed the strongest inhibitory
impact on PDHc activity. Medium-chain and dicarboxylic acyl-CoAs
were less effective inhibitors. Neither acylcarnitines nor organic acids
that were investigated had an inﬂuence on enzyme activity (Table 2).3.5. Impact of short- and medium-chain acyl-CoAs on alpha-
ketoglutarate dehydrogenase complex (KGDHc)
Next, we studied the impact of SMOAAs (each 250, 500, and
1000 μmol/L, in Tris–HCl, adjusted to pH 7.4) on KGDHc activity. In
analogy to the inhibition studies using PDHc, all investigated acyl-
CoAs inhibited KGDHc activity depending on chain length and number
of carboxylic groups (Fig. 5). Unbranched chain dicarboxylic and
short-chain monocarboxylic acyl-CoAs revealed the strongest inhibi-
tory impact on KGDHc activity. Unbranched medium-chain mono-
carboxylic acyl-CoAs and branched-chain mono- and dicarboxylic
acids were less effective. All investigated acylcarnitines inhibited
KGDHc activity by about 25%. Organic acids did not affect enzyme
activity (Table 2).
4. Discussion
The aim of this study was to investigate the impact of SMOAAs on
central components of the mitochondrial energy metabolism namely
Fig. 4. Impact of short- and medium-chain acyl-CoAs (each 250, 500, and 1000 μmol/L, in Tris–HCl, adjusted to pH 7.4) on PDHc activity. All investigated acyl-CoAs inhibited PDHc
activity. The inhibitory effect was critically dependent on chain length and number of carboxylic groups. Short-chain monocarboxylic acyl-CoAs revealed the strongest inhibitory
effect on PDHc activity. Medium-chain and dicarboxylic acyl-CoAs were less effective inhibitors. Activities are given as percent of control. All data are expressed as mean±S.D.,
experiments were performed in triplicates.
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chain. All investigated acyl-CoAs had an inhibitory impact on PDHc
and KGDHc activity. However, effect sizes were critically dependent on
chain length and number of functional groups. In previous studies, we
have shown that propionyl-CoA and glutaryl-CoA uncompetitively
inhibit both PDHc and KGDHc. The most likely mechanism is product
feedback inhibition of the E2 subunits [4,6]. Due to the fact that
increasing structural similarity to glutaryl-CoA or propionyl-CoA
resulted in increasing inhibitory potential on the respective enzyme
activity, it seems likely that the inhibitory effect of other acyl-CoAs is
based on the same mechanism. In contrast, all organic acids
investigated in this study had no effect on PDHc or KGDHc activity.
Whereas the corresponding acylcarnitines did not also affect PDHc
activity, they showed a general and small inhibitory impact on KGDHc
activity.
Next, we investigated the impact of SMOAAs on single enzyme
complexes I–V of the respiratory chain. All studied acylcarnitines and
organic acids (except for malonic acid) did not affect the activity of
respiratory chain complexes. Again, only a few acyl-CoAs revealed an
impact on enzyme activities. Malonyl-CoA and butyryl-CoA inducedFig. 5. Impact of short- and medium-chain acyl-CoAs (each 250, 500, and 1000 μmol/L, in Tris
activity depending on chain length and number of carboxylic groups. Unbranched chain dic
impact on KGDHc activity. Unbranched medium-chain monocarboxylic acyl-CoAs and branch
as percent of control. All data are expressed as mean±S.D., experiments were performed inan activation of complex III activity, and acetyl-CoA activated complex
II. Previous studies have shown that complex II and complex III activity
can be activated by speciﬁc phospholipids [28–31]. In addition,
activation of complex II by succinyl-CoA was demonstrated [32]. The
above described activating impact of acetyl-CoA, malonyl-CoA, and
butyryl-CoA may base on a similar mechanism.
However, the most intriguing ﬁnding of our study was the
inhibition of complex III by octanoyl-CoA. Octanoyl-CoA apparently
displays no structural similarity to the substrates ubiquinone and
cytochrome c or any known inhibitor of complex III. Consistently,
competition experiments with varying substrate concentrations
revealed that the inhibition was noncompetitive regarding DBH, i.e.
the inhibitor reversibly binds to both the enzyme–substrate complex
and the enzyme itself, and uncompetitive regarding cytochrome c, i.e.
the inhibitor binds to the enzyme–substrate complex, but not the free
enzyme. Therefore, binding of cytochrome c but not binding of DBH to
complex III seems to be obligatory for the inhibition by octanoyl-CoA.
This ﬁndingmay be explained by the fact that binding of cytochrome c
is obligatory for the electron ﬂow of the high-potential chain and,
thereby, catalytic activity of the enzyme.–HCl, adjusted to pH 7.4) on KGDHc activity. All investigated acyl-CoAs inhibited KGDHc
arboxylic and short-chain monocarboxylic acyl-CoAs revealed the strongest inhibitory
ed-chain mono- and dicarboxylic acid were less effective inhibitors. Activities are given
triplicates.
Table 2
Impact of short- and medium-chain acylcarnitines and organic acids on PDHc and
KGDHc activity
PDHc KGDHc
M (%)±SD (%) M (%)±SD (%)
l-Acetyl-carnitine 87±3 76±2
Propionyl-carnitine 94±2 76±1
Butyryl-carnitine 98±1 78±1
Isovaleryl-carnitine 105±5 78±2
Valeryl-carnitine 97±1 78±2
Hexanoyl-carnitine 115±4 85±3
Octanoyl-carnitine 101±2 70±3
d-Acetyl-carnitine 99±1 85±7
Acetic acid 110±4 101±1
Propionic acid 104±6 99±1
Butyric acid 119±2 102±6
Isovaleric acid 104±4 101±2
Valeric acid 99±17 96±1
Hexanoic acid 101±2 95±3
Malonic acid 113±3 99±0
Methylmalonic acid 117±6 101±4
Glutaric acid 106±7 94±2
3-Hydroxyglutaric acid 112±3 89±2
Neither organic acids nor acylcarnitines (each 1mmol/L, in Tris–HCl pH 7.4) affected the
activity of PDHc. All investigated acylcarnitines inhibited KGDHc activity by about 25%.
Organic acids did not affect enzyme activity. Activities are given as percent of control.
Data are expressed as mean±S.D. (n=4).
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in the absorption spectrum of reduced complex III in analogy to
funicolsin [33] and ilicicolin H [34] both inhibiting ubiquinone
reduction at center N (mitochondrial matrix directed [35]). The blue
shift of the gamma band indicates that reduction of cytochrome c
(peak at 415 nm) and cytochrome b (peak at 429 nm) was inhibited.
The alpha band displayed a minimum at 561 nm that is likely to refer
to heme b562. The cytochrome c peak at 555 nm was less affected.
Difference spectra of oxidized and in presence of an inhibitor reduced
enzyme showed a strong decrease of cytochrome b peak in the alpha
band at 560 nm and only a mild reduction of cytochrome c peak at
555 nm. These observations suggest that the inhibition of complex III
activity by octanoyl-CoA is mediated by an inhibited reduction of
heme b562 that is located at center N [36]. Therefore, we postulate that
the inhibitory impact of octanoyl-CoA is based on an interaction with
center N of complex III.
Octanoyl-CoA pathophysiologically accumulates in medium-chain
acyl-CoA dehydrogenase (MCAD) deﬁciency but the precise intracel-
lular, and particularly hepatic, concentration of this metabolite is yet
unknown. The only study investigating the hepatic acyl-CoA proﬁles
in MCAD deﬁciency did not provide data for octanoyl-CoA [37].
Though MCAD deﬁciency is the most frequent error of fatty acid
oxidation [38] with an estimated frequency of 1:6,000 to 1:10,000
Caucasian births, the pathophysiology of this disorder is yet poorly
understood. During late stages of fasting, fatty acids are used for
hepatic ketone synthesis and to provide 80% of total body energy
demands. Patients with MCAD deﬁciency have a mainly hepatic type
of presentation which is precipitated by episodes that are likely to
induce catabolic state, such as febrile illness, vomiting, and encepha-
lopathy [39–41]. Approximately 25% of untreated patients have died
suddenly and unexpectedly, whereas a similar percentage of patients
may remain free of symptoms throughout life. During catabolic state,
the manifestation of severe symptoms such as lethargy and nausea
develops in association with the marked increase in fatty acids,
whereas ketone bodies remain low [39,42]. Hypoglycemia may
develop shortly thereafter; however, it should be stressed that
patients may become dangerously ill before hypoglycemia occurs.
This suggests that toxic effects of elevated plasma free fatty acids or
intracellularly accumulating acyl-CoA esters might be involved in the
pathogenesis of MCAD deﬁciency—in addition to hypoketotic hypo-glycemia. Interestingly, electron microscopical studies of hepatic
mitochondria fromMCAD deﬁcient patients during metabolic decom-
pensation revealed characteristic features of a severely disturbed
mitochondrial energy metabolism [43–47].
Elevated concentrations of octanoyl-CoA are also found in three
additional conditions, i.e. multiple acyl-CoA dehydrogenase deﬁ-
ciency, Reye syndrome, and Jamaican vomiting sickness. Multiple
acyl-CoA dehydrogenase deﬁciency is caused by inherited deﬁciency
of electron transfer ﬂavoprotein (ETF) or ETF-Q causing loss or reduced
activity of all mitochondrial FAD-dependent acyl-CoA dehydrogenases
[48,49]. Due to the signiﬁcant impairment of energy metabolism,
multiple organ failure is frequently found. The etiology of Reye
syndrome, a combination of liver disease and noninﬂammatory
encephalopathy with sudden onset [50], is unknown but a strong
epidemiologic association to the ingestion of acetylaspartic acid
during antecendent varicella or inﬂuenza-like illnesses has been
shown [51–54] although not undoubted [55,56]. Multiple site
inhibition of mitochondrial enzymes of energy metabolism has been
considered which is supported by the ﬁnding of disrupted mitochon-
drial cristae [57], the sites of membrane-associated acyl-CoA dehy-
drogenases of branched-chain and fatty acid oxidation [58,59].
Jamaican vomiting sickness is peculiar to Jamaica and is caused by
inhibition of FAD-dependent acyl-CoA dehydrogenases by hypoglycin
A intoxication following ingestion of unriped Ackee fruit [60]. Fatty
change of the liver, kidneys, and other organs is also a prominent
feature in this intoxicationwhich has a highmortality rate. In addition
to octanoyl-CoA, other short- and medium-chain acyl-CoAs are found
to be elevated in these conditions [37,61].
Although impairment of mitochondrial energy metabolism by
accumulating short- and medium-chain acyl-CoAs – especially
octanoyl-CoA–may not be the ﬁrst step in the pathogenesis of
MCAD deﬁciency, multiple acyl-CoA dehydrogenase deﬁciency, Reye
syndrome, and Jamaican vomiting sickness, it seems likely to assume
that they act synergistically with other toxic metabolites inducing a
secondary severe inhibition of key enzymes of mitochondrial energy
metabolism resulting in multiorgan failure or even death if untreated.
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